Download MendeleyIdentification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase.
Schroeder, G.M., Chen, X.T., Williams, D.K., Nirschl, D.S., Cai, Z.W., Wei, D., Tokarski, J.S., An, Y., Sack, J., Chen, Z., Huynh, T., Vaccaro, W., Poss, M., Wautlet, B., Gullo-Brown, J., Kellar, K., Manne, V., Hunt, J.T., Wong, T.W., Lombardo, L.J., Fargnoli, J., Borzilleri, R.M.(2008) Bioorg Med Chem Lett 18: 1945-1951
- PubMed: 18289854
- DOI: https://doi.org/10.1016/j.bmcl.2008.01.121
- Primary Citation of Related Structures:
3C1X - PubMed Abstract:
An amide library derived from the pyrrolo[2,1-f][1,2,4]triazine scaffold led to the identification of modest inhibitors of Met kinase activity. Introduction of polar side chains at C-6 of the pyrrolotriazine core provided significant improvements in in vitro potency. The amide moiety could be replaced with acylurea and malonamide substituents to give compounds with improved potency in the Met-driven GTL-16 human gastric carcinoma cell line. Acylurea pyrrolotriazines with substitution at C-5 demonstrated single digit nanomolar kinase activity. X-ray crystallography revealed that the C-5 substituted pyrrolotriazines bind to the Met kinase domain in an ATP-competitive manner.
Organizational Affiliation:
Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543-4000, USA. gretchen.schroeder@bms.com
